E1 ReplicatedModerate confidencePEM not requiredRCTPeer-reviewedMachine draft
Standard · 3 min
Plasma leptin in chronic fatigue syndrome and a placebo-controlled study of the effects of low-dose hydrocortisone on leptin secretion.
Cleare, A J, O'Keane, V, Miell, J · Clinical endocrinology · 2001 · DOI
Quick Summary
This study looked at leptin, a hormone that affects appetite and weight, in people with ME/CFS. Researchers compared leptin levels in ME/CFS patients with healthy controls, then gave some patients a low dose of hydrocortisone (a steroid) to see if it changed leptin levels. They found that leptin levels were similar between patients and healthy people at baseline, but hydrocortisone increased leptin levels in ME/CFS patients, especially in those who felt better with the treatment.
Why It Matters
This study provides insight into potential neuroendocrine dysregulation in ME/CFS and explores whether low-dose hydrocortisone therapy works through glucocorticoid pathways. The association between leptin response and clinical improvement may help identify which patients are likely to benefit from hydrocortisone, potentially enabling more personalized treatment approaches.
Observed Findings
Baseline plasma leptin was not significantly different between CFS patients (mean 13.8 ng/ml) and controls (mean 10.2 ng/ml).
Hydrocortisone treatment combined caused a statistically significant increase in leptin compared to placebo.
The 10 mg hydrocortisone dose showed a significant effect on leptin levels; the 5 mg dose did not reach statistical significance when analysed separately.
Clinical responders to hydrocortisone showed a significantly greater rise in leptin than non-responders.
Inferred Conclusions
Leptin metabolism itself may not be fundamentally altered in ME/CFS at baseline, suggesting it is not a primary driver of the condition.
Low-dose hydrocortisone increases leptin levels in CFS patients, indicating a biological effect of glucocorticoid administration.
The greater leptin response in clinical responders may reflect increased glucocorticoid receptor sensitivity or better preserved HPA axis responsiveness in that subgroup.
Leptin response to hydrocortisone may serve as a biomarker of physiological hypocortisolism and treatment response in certain ME/CFS patients.
Remaining Questions
Why did only the 10 mg hydrocortisone dose show a significant leptin effect, and what is the optimal dosing for maximum therapeutic benefit?
What This Study Does Not Prove
This study does not prove that leptin dysfunction causes ME/CFS, as baseline leptin levels were similar in patients and controls. It also does not establish that hydrocortisone is an effective therapy for all ME/CFS patients—only that it causes biochemical changes in some individuals. Correlation between leptin rise and clinical response does not prove causation; both may reflect a third underlying factor such as improved glucocorticoid receptor function.
Tags
Symptom:Fatigue
Biomarker:Blood Biomarker
Method Flag:PEM Not DefinedSmall SampleExploratory Only
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Does the leptin response predict clinical improvement prospectively, or is it merely an associated marker in retrospective responders?
What proportion of ME/CFS patients have the glucocorticoid receptor sensitivity or HPA axis characteristics associated with treatment response?
What are the long-term safety and efficacy outcomes of low-dose hydrocortisone therapy in ME/CFS, and does leptin response correlate with sustained clinical benefit?